MINNEAPOLIS, MN / ACCESSWIRE / April 3, 2018 / DiaMedica Therapeutics Inc. ('DiaMedica') (TSX-V: DMA) (OTCQB: DMCAF), today announced that Mr. Rick Pauls, President and CEO, will present at The MicroCap Conference at the Essex House, 160 Central Park South New York on Tuesday April 10th at 12:30pm ET.
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.
For more information please visit www.microcapconf.com.
About DiaMedica Therapeutics:
DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica's lead product candidate DM199, a recombinant (synthetic) form of the KLK1 protein, is in clinical development for the treatment of acute ischemic stroke and chronic kidney diseases.
DiaMedica's shares are listed on the TSX Venture Exchange under the trading symbol 'DMA' and on the OTCQB under the trading symbol 'DMCAF.' For more information, please visit www.diamedica.com. Follow us on social media - Twitter, LinkedIn.
News Compliments of ACCESSWIRE.
For further information, please contact:
Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Two Carlson Parkway, Suite 260
Minneapolis, MN
Phone: (617) 899-5941
info@diamedica.com
Tweet this!
SOURCE: DiaMedica Therapeutics Inc.
